Clinical Trials for Uterine Cancer

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with ECOG 0–1 and measurable advanced HR+/HER2− breast cancer or selected CCNE1-amplified solid tumors receive oral AVZO-021, an investigational CDK2 inhibitor, alone or in cohort-specific combinations. Combinations include endocrine therapy, CDK4/6 inhibitors, sacituzumab govitecan, or carboplatin; eligibility and prior-treatment requirements vary by cohort.

ClinicalTrials.gov ID: NCT05867251

A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, measurable solid tumors and ECOG performance status 0–2 receive intravenous DM002 every 21 days in dose-escalation or expansion cohorts. DM002 is an investigational bispecific antibody–drug conjugate targeting MUC1 and HER3 with a topoisomerase I inhibitor payload; patients previously treated with a topoisomerase I–payload ADC are generally excluded.

ClinicalTrials.gov ID: NCT06751329

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HER2-expressing (IHC 1+–3+) locally advanced or metastatic endometrial cancer that has progressed after at least one systemic therapy receive pembrolizumab (PD-1 inhibitor), lenvatinib (multikinase inhibitor), and an investigational autologous HER2-targeted dendritic-cell vaccine. One arm also receives N-803, an investigational IL-15 superagonist intended to stimulate tumor-killing immune cells.

ClinicalTrials.gov ID: NCT06253494

A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with CLDN6-positive platinum-resistant or refractory ovarian cancer, or advanced testicular or endometrial cancer, receive weekly CTIM-76. This investigational bispecific antibody binds CLDN6 on tumor cells and CD3 on T cells to direct T-cell killing.

ClinicalTrials.gov ID: NCT06515613

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls patients with CLDN6-positive advanced ovarian, fallopian tube, peritoneal, or endometrial cancer or germ cell tumors that have progressed after standard therapy. Patients receive intravenous or subcutaneous XmAb541, a bispecific antibody that binds CLDN6 on tumor cells and CD3 on T cells.

ClinicalTrials.gov ID: NCT06276491

A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Patients with measurable recurrent or persistent endometrial carcinoma after 1–2 prior systemic therapies are assigned to biomarker-matched cohorts. Open cohorts evaluate atezolizumab (anti–PD-L1) plus talazoparib (PARP inhibitor) for high genomic loss of heterozygosity or tiragolumab (anti-TIGIT) for MSI-high/high-TMB tumors, and inavolisib (PI3Kα inhibitor) plus letrozole for PIK3CA-mutant tumors or giredestrant (ER degrader) plus abemaciclib (CDK4/6 inhibitor) for RB1-intact, low-grade ER-positive tumors.

ClinicalTrials.gov ID: NCT04486352

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent clear cell or endometrioid ovarian cancer or clear cell or grade 1 endometrioid endometrial cancer after 1–3 prior cytotoxic regimens receive oral tuvusertib, an ATR inhibitor, plus oral ZEN-3694, a BET inhibitor. Dose escalation also permits platinum-resistant high-grade serous ovarian cancer; expansion enrolls separate ARID1A-altered and wild-type cohorts.

ClinicalTrials.gov ID: NCT05950464

A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors that have progressed after at least one systemic therapy receive FT836, an off-the-shelf, induced pluripotent stem cell–derived CAR T-cell therapy targeting MICA/MICB. FT836 is given alone or with paclitaxel, cetuximab, or trastuzumab, including paclitaxel–antibody combinations.

ClinicalTrials.gov ID: NCT07216105

Phase I/IB Study of Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable recurrent high-grade endometrial cancer or uterine carcinosarcoma after platinum therapy receive paclitaxel plus dose-escalated zanzalintinib, with zanzalintinib maintenance available if disease does not progress. Zanzalintinib is an investigational oral multikinase inhibitor targeting VEGFR2, MET, and the TAM kinases TYRO3, AXL, and MER.

ClinicalTrials.gov ID: NCT06795009

A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, measurable metastatic or locally advanced head and neck, lung, gastrointestinal, pancreatic, cervical, endometrial, or urothelial cancer receive STRO-004 alone or with pembrolizumab. STRO-004 is a tissue factor–targeted antibody–drug conjugate that delivers the topoisomerase I inhibitor exatecan.

ClinicalTrials.gov ID: NCT07227168